| Primary | Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure | The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-3.1± 2.71
- OG001-10.2± 2.69
- OG002-13.6± 2.70
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | ANCOVA | | 0.007 | Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo. | | | | | | | | | | | | No | Superiority or Other | | | | | ANCOVA |
|
| Secondary | Change From Baseline in Glycosylated Hemoglobin (HbA1c) | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward. | Posted | | Least Squares Mean | Standard Error | percentage glycosylated hemoglobin | | Baseline and Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure | The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring | The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring | The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring | The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mm Hg | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Percentage of Participants Requiring Rescue Glycemic Therapy | Percentage of participants requiring rescue glycemic therapy during study. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. | Posted | | Number | | percentage of participants | | 24 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Time to First Glycemic Rescue | The time to the first instance of participants requiring glycemic rescue during study. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. | Posted | | Median | Inter-Quartile Range | Days | | 24 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in HbA1c | The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward. | Posted | | Least Squares Mean | Standard Error | percentage glycosylated hemoglobin | | Baseline and Weeks 2, 4, 6, 8, 12, 16 and 20 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline in Fasting Plasma Glucose | The change between the fasting plasma glucose value collected at each week indicated relative to baseline. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward. | Posted | | Least Squares Mean | Standard Error | mmol/L | | Baseline and Weeks 2, 4, 6, 8, 12, 16, 20, and 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT) | The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mmol/L | | Baseline and Weeks 6 and 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT | The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | mmol*hours/L | | Baseline and Weeks 6 and 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT | The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | pmol*hours/L | | Baseline and Weeks 6 and 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT | The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | nmol*hours/L | | Baseline and Weeks 6 and 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT | The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | pmol*hr/mmol | | Baseline and Weeks 6 and 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |
| Secondary | Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT | The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage. | The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases. | Posted | | Least Squares Mean | Standard Error | ng*hours/L | | Baseline and Weeks 6 and 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo QD | Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks. | | OG001 | Azilsartan Medoxomil 40 mg QD | Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks. | | OG002 | Azilsartan Medoxomil 80 mg QD | Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks. |
| |